Sex Differences in Bystander Cardiopulmonary Resuscitation and Survival to Hospital Discharge for Public Out-of-Hospital Cardiac Arrests in North Carolina and Singapore
Abstract Body: Introduction: Although it is known that women are less likely than men to receive bystander cardiopulmonary resuscitation (BCPR) in public, few studies have examined differences in receipt of BCPR and survival to hospital discharge for public out-of-hospital cardiac arrests (OHCAs) by patient sex between distinct regions. Objectives: We assessed if patient sex was associated with BCPR (primary outcome) and survival to hospital discharge (secondary outcome) for public OHCAs in North Carolina (NC) and Singapore (SG). We hypothesized that females in both regions would have lower receipt of BCPR and were less likely to survive to hospital discharge compared with men. Methods: We conducted a retrospective cohort study of the Cardiac Arrest Registry to Enhance Survival dataset (NC, 2013-2022) and Pan-Asian Resuscitation Outcomes Study (SG, 2010-2020). We excluded pediatric, traumatic, emergency medical services (EMS) witnessed cases, arrests in healthcare facilities and residential cases. Using logistic regression, we examined the association of sex with BCPR and survival to hospital discharge controlling for potential confounding variables such as age, race and the year of arrest. Results: There were 65,627 OHCAs in NC; upon exclusion 6,828 remained (78% males; mean age: 57±15, males, 54.7±18, females). In SG, there were 24,177 OHCAs; upon exclusion 3,617 cases remained (87% males; mean age: 57±14, males, 61±16.4, females). In NC, public BCPR rates were 48% for males and 44% for females. Females had a 13% adjusted lower odds of receiving less BCPR (adjusted OR 0.87 (CI 0.77, 0.99)). In SG, BCPR rates were 59% for males and 52% for females. Similarly, females had a 22% lower adjusted odds of receiving BCPR (adjusted OR 0.78 (CI 0.62, 0.98)). In NC, survival to hospital discharge rates for public OHCAs were 24% for males and 26% for females. Females had a 17% lower adjusted odds ratio of survival to hospital discharge compared to males (adjusted OR 1.17 (95% CI 1.01, 1.35)). In SG, public survival to hospital discharge rates were 12% for males and 9% for females. Females had a 36% adjusted lower odds of survival to hospital discharge compared to males (adjusted OR 0.64 (95% CI 0.43, 0.94)). Conclusion: In public OHCAs, females were less likely to receive BCPR than males in both regions. However, females were less likely to survive to hospital discharge in SG, whereas the opposite was seen in NC. Further research is needed to elucidate factors for these differences.
Wee, Glenda
( Duke-NUS Medical School
, Singapore
, Singapore
)
Ostbye, Truls
( Duke University
, Hillsborough
, North Carolina
, United States
)
Hart, Lauren
( Duke University School of Medicine
, Durham
, North Carolina
, United States
)
Hansen, Carolina
( Duke University
, Durham
, North Carolina
, United States
)
Shahidah, Nur
( Singapore General Hospital
, Singapore
, Singapore
)
Starks, Monique
( Duke University
, Hillsborough
, North Carolina
, United States
)
Granger, Christopher
( DUKE CLINICAL RESEARCH INSTITUTE
, Durham
, North Carolina
, United States
)
Ong, Marcus
( SINGAPORE GENERAL HOSPITAL
, Singapore
, Singapore
)
Blewer, Audrey
( Duke University
, Durham
, North Carolina
, United States
)
Author Disclosures:
Glenda Wee:DO NOT have relevant financial relationships
| Truls Ostbye:DO NOT have relevant financial relationships
| Lauren Hart:No Answer
| Carolina Hansen:No Answer
| Nur Shahidah:DO NOT have relevant financial relationships
| Monique Starks:DO NOT have relevant financial relationships
| Christopher Granger:DO have relevant financial relationships
;
Consultant:Abbvie, Abiomed, Alnylam Pharmaceuticals, Amgen:Active (exists now)
; Individual Stocks/Stock Options:Tenac.io:Active (exists now)
; Research Funding (PI or named investigator):Philips and Roche :Active (exists now)
; Research Funding (PI or named investigator):Pfizer:Active (exists now)
; Research Funding (PI or named investigator):Novartis:Active (exists now)
; Research Funding (PI or named investigator):Lilly:Active (exists now)
; Research Funding (PI or named investigator):Janssen :Active (exists now)
; Research Funding (PI or named investigator):Bristol Myers Squibb - research and consutling:Active (exists now)
; Research Funding (PI or named investigator):Boehringer Ingelheim :Active (exists now)
; Research Funding (PI or named investigator):Alnylam:Active (exists now)
; Consultant:Philips, REATA, Roche, Veralox :Active (exists now)
; Consultant:, Novo Nordisk, NephroSynergy, Novartis, Pfizer:Active (exists now)
; Consultant:Medscape, Medtronic Inc., Merck, NIH:Active (exists now)
; Consultant:, Cardionomic, CeleCore Therapueutics, HengRui, Janssen:Active (exists now)
; Consultant:, Anthos, Bayer, Boehringer Ingelheim, Boston Scientific:Active (exists now)
| Marcus Ong:DO NOT have relevant financial relationships
| Audrey Blewer:DO have relevant financial relationships
;
Research Funding (PI or named investigator):Laerdal Foundation:Active (exists now)
; Research Funding (PI or named investigator):NIH ORWH:Active (exists now)
; Other (please indicate in the box next to the company name):In Kind - American Heart Association:Active (exists now)
; Other (please indicate in the box next to the company name):In Kind - World Point:Expected (by end of conference)
; Research Funding (PI or named investigator):American Heart Association:Active (exists now)
; Research Funding (PI or named investigator):NIH NHLBI:Active (exists now)